Companies Seeking Solutions To Emerging Drug Resistance

PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new

Written byStephen Hoffert
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share


PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999.
Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new compounds. But in the last decade, physicians and epidemiologists have seen resistance to antibiotics surge. Along with some pharmaceutical companies, small biotechnology firms now lead the drive against drug- resistant bacteria.

Data collected by the Synercid Microbiology Assessment of Resistance Trends (SMART)--a surveillance project run by the State University of New York (SUNY) at Buffalo and the University of Iowa College of Medicine--show increasing drug resistance in the United States. More than 31 percent of 17,000 bacterial isolates ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026, Issue 1

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs
Graphic of three DNA helices in various colors

An Automated DNA-to-Data Framework for Production-Scale Sequencing

illumina
Exploring Cellular Organization with Spatial Proteomics

Exploring Cellular Organization with Spatial Proteomics

Abstract illustration of spheres with multiple layers, representing endoderm, ectoderm, and mesoderm derived organoids

Organoid Origins and How to Grow Them

Thermo Fisher Logo

Products

Brandtech Logo

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control

Biotium Logo

Biotium Launches GlycoLiner™ Cell Surface Glycoprotein Labeling Kits for Rapid and Selective Cell Surface Imaging

Colorful abstract spiral dot pattern on a black background

Thermo Scientific X and S Series General Purpose Centrifuges

Thermo Fisher Logo
Abstract background with red and blue laser lights

VANTAstar Flexible microplate reader with simplified workflows

BMG LABTECH